Otsuka announces record-setting pharma IPO; Dendreon shares leap on CMS assessment;

@FiercePharma: FDA blocks Claris imports on plant troubles. Report | Follow @FiercePharma 

> Japanese drugmaker Otsuka Holdings said it will sell about $2.8 billion worth of shares in December, the world's largest initial public offering in the pharmaceuticals sector. Article | Report

> Shares of biotech drugmaker Dendreon jumped after Medicare officials issued a mostly positive assessment of the company's prostate cancer therapy, setting the stage for the government to pay for thousands of patients to receive the drug. News

> Although no product was explicitly mentioned, the FDA's marketing watchdog found plenty to dislike about a white paper and other unbranded materials circulated by Tercica, a subsidiary of the Ipsen Group. Item

> Spanish pharmaceutical firm Grifols has bowed to a class-action suit filed by some shareholders of its bid target Talecris by improving the share component of the offer for its U.S. rival. Story

> Centocor Ortho Biotech, a Johnson & Johnson subsidiary, has asked the FDA to expand the use of the injectable drug Simponi in treating patients with active psoriatic arthritis. Article

> BASF, the world's biggest chemicals maker, can't be sued by a group of customers who claim they paid too much for vitamins during a price-fixing cartel in the 1990s, a U.K. appeals court ruled. Report

Biotech News

 @FierceBiotech:  Biotech IPOs struggling as one is pulled and another falls short. News | Follow @FierceBiotech

 @JohnCFierce: Ceregene gains $11.5M in venture cash for PH2b Parkinson's drug trial. Story | Follow @JohnCFierce

> OncoVista to sell AdnaGen unit for up to $65M. News

> Upcoming Benlysta decision sparks HGS buyout talk. Report 

> Novo Nordisk plans $100M expansion of Beijing R&D site. Item 

> Spencer board OKs buyout. Story 

> ESBATech spin-out Delenex rounds up $14M. Item  

And Finally... Does it matter if Europe's top medicines regulator is without an executive director for six months? Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.